Background
==========

Combination anti-retroviral therapy (ART) has reduced the mortality from cytomegalovirus (CMV) opportunistic infections in HIV positive patients \[[@B1]\]. CMV continues to result in morbidity and mortality in patients initiating ART at low CD4 T-cell counts, occasionally as a result of immune reconstitution inflammatory syndrome (IRIS). We present a case of unmasking CMV-IRIS in an HIV-infected patient following ART initiation.

Appendicitis occurs with increased frequency in HIV infected patients as compared to HIV uninfected patients \[[@B2]\]. A number of opportunistic pathogens or AIDS related malignancies have been shown to cause appendicitis in HIV-infected patients, including Kaposi sarcoma \[[@B3]\], Strongyloides \[[@B4]\], Mycobacterium tuberculosis \[[@B5]\], and Mycobacterium avium complex \[[@B6]\].

Tucker et al. published the first report of CMV appendicitis in an HIV positive patient in 1989 \[[@B7]\] and, since that time, ten additional reports of CMV appendicitis in HIV patients have been described in the literature \[[@B8]-[@B16]\]. Ten of the eleven reported patients presented with right lower quadrant pain and in eight of them fever was noted at the time of presentation (see Table  [1](#T1){ref-type="table"}) \[[@B7]-[@B16]\]. CMV appendicitis typically presents with similar symptoms \[[@B17],[@B18]\], but may have a higher mortality than other identified etiologies of appendicitis \[[@B12],[@B17]\].

###### 

CMV appendicitis cases reported in HIV-infected patients from 1988 to present

  **Reference/Year**                    **Age/Gender**   **ARVs at diagnosis (duration)**  **Clinical syndrome**                                    **Diagnosis**                                      **Treatment**                                                                                           **Outcome**
  ------------------------------------ ---------------- ---------------------------------- -------------------------------------------------------- -------------------------------------------------- ------------------------------------------------------------------------------------------------------- ------------------------------------------------------------
  \[[@B6]\] 1989                           35 yo M                      No                 Abdominal pain, TTP in RLQ, rebound                      Histology                                          Laparoscopic appendectomy with IV and oral antibiotics                                                  Abscess; Recovery then readmission and death 25 days later
  \[[@B7]\] 1988 (Published in 1991)       50 yo M                      No                 Fever, RLQ pain, rebound tenderness, RLQ mass            Histology                                          Exploratory laparotomy; IV antibiotics ganciclovir 5×/week ("maintenance therapy") when CMV confirmed   Periappendiceal abscess; Recovery
  \[[@B8]\] 1990                           28 yo M                Yes (5 weeks)            RLQ pain, rebound                                        Histology                                          Exploratory laparotomy, IV antibiotics with appendectomy                                                Recovery
  \[[@B9]\] 1991                           31 yo M                      No                 Fever, RLQ pain, rebound, guarding                       Histology, in situ hybridization with CMV probes   Appendectomy                                                                                            Recovery
  \[[@B10]\] 1993                          38 yo M                      NR                 RLQ pain, fever TTP at McBurney's point                  Histology, IHC (monoclonal anti-CMV antibody)      IV antibiotics and observation; Exploratory laparotomy with appendectomy; ganciclovir                   Recovery
  \[[@B11]\] 1994 Patient 1                48 yo M                      NR                 Lower abdominal pain, fever, septic shock                Histology                                          Exploratory laparotomy with appendectomy, ganciclovir, imipenem, inotropes.                             Perforation; Death
  \[[@B11]\] 1994 Patient 2                27 yo M                      NR                 Periumbilical pain, nausea, vomiting, peritoneal signs   Histology, IHC                                     Exploratory laparotomy with appendectomy                                                                Death
  \[[@B12]\] 1995                          34 yo M            Yes (unknown duration)       RLQ pain, fever                                          Histology CMV PCR in WBC                           Laparoscopic appendectomy                                                                               Recovery
  \[[@B13]\] 1997                          30 yo M                      NR                 RLQ pain, fever, nausea, vomiting                        Histology                                          Appendectomy, post-op ganciclovir                                                                       Recovery
  \[[@B14]\] 1997                          29 yo M                      NR                 Right sided abdominal pain                               Histology, immunofluorescence                      Appendectomy                                                                                            Abscess and perforation; Recovery
  \[[@B15]\] 2004                          37 yo M                      NR                 Fever, abdominal pain, rebound and guarding over RLQ     Histology, immunostaining                          Appendectomy; IV ganciclovir                                                                            Recovery
  Present case                             38 yo F                Yes (2 weeks)            RLQ pain, anorexia, nausea, fever                        Histology, CMV viral staining                      Laparoscopic appendectomy, IV antibiotics peri-operatively, valganciclovir (2 weeks)                    Perforation; Full recovery

NR: not reported; M: male; F: female; RLQ: right lower quadrant; TTP: tenderness to palpation, IHC: immunohistochemistry. WBC: white blood cells.

In a study of autopsies of HIV positive patients, CMV was the most commonly isolated opportunistic infection, though the vast majority of the patients were asymptomatic while alive \[[@B19]\]. In this particular patient, the biopsy demonstrated substantial inflammation and necrosis as well as abundant CMV positive cells, making CMV the likely cause of appendicitis, rather than an incidental finding.

Case presentation
=================

The patient enrolled in an Institutional Review Board-approved, prospective study of HIV-1 infected, ART naïve patients with CD4 count below 100 cells/μL in Bethesda, Maryland, one month after a new HIV diagnosis. At the time of enrollment, the patient complained of a 23 Kg weight loss and had a CD4 count of 72 T cells/μL and a plasma HIV-RNA of 284,010 copies/ml. The viral genotype showed wild type virus and she was initiated on Efavirenz/Emtricitabine/Tenofovir. Her blood CMV PCR was negative at baseline, CMV IgG was positive (4.460 U) and CMV IgM was negative.

Two weeks after ART initiation, the patient returned to care with a four-day history of cramping abdominal pain predominantly in the right lower quadrant as well as nausea and anorexia without chills, vomiting, diarrhea, urinary symptoms, or vaginal discharge. The patient was febrile (38.8°C) and tachycardic (124 bpm). Abdominal exam revealed normoactive bowel sounds with direct tenderness to palpation in the lower abdominal quadrants (right more than left). Guarding, rigidity, and rebound were absent and the remainder of the exam was noncontributory.

CBC demonstrated leukopenia (leukocytes 2.58 K/μL) with 0.8% immature granulocytes. Alkaline phosphatase was 186 IU/L (up from 140 IU/L at baseline), with normal liver and pancreatic enzyme levels. The CRP had increased to 8.52 mg/dl from 1.95 mg/dl at baseline. Blood CMV PCR became detectable at 750 copies/ml. An abdominal CT scan demonstrated thickening of the appendix with fat stranding and mild lymphadenopathy of the pelvic sidewall, predominantly on the right side consistent with appendicitis. The patient underwent an uncomplicated laparoscopic appendectomy, received IV metronidazole and vancomycin perioperatively, and was discharged on post-op day three.Pathologic examination of the patient's appendiceal tissue demonstrated appendicitis with sealed perforation and evidence of CMV infection. There was marked lymphoid hyperplasia with mature lymphocytes and plasma cells (Figure  [1](#F1){ref-type="fig"}A). Immunohistochemistry showed that the lymphocytic infiltration was composed of a mixture of T cells and polyclonal B cells with equal distribution of immunoglobulin light chain kappa and lambda staining, making lymphoma unlikely. Neutrophilic infiltration was scarce. In situ hybridization for EBV virus encoded small RNA (EBER) was negative. CMV viral staining was positive in numerous cells showing typical cytopathic changes of CMV infection including cellular and nuclear enlargement and nuclear inclusions (Figure  [1](#F1){ref-type="fig"}B), and were distributed throughout the full thickness of the bowel wall.

![**Histopathologic examination of the appendix. A**: Hematoxylin and eosin stain showing lymphoplasmacytic hyperplasia and scattered enlarged cells (arrow) with features characteristic of CMV-induced cytopathic changes. **B**: CMV immunostaining demonstrating CMV-infected cells throughout the full thickness of the bowel wall (arrows). Figure inset illustrates an infected cell at higher power view depicting cellular and nuclear enlargement with nuclear inclusions.](1471-2334-14-313-1){#F1}

The patient returned to clinic after 3 weeks with complaints of increased abdominal pain and two episodes of hematochezia. Valganciclovir was initiated for suspected CMV colitis (endoscopy could not be performed due to the recent abdominal surgery). The patient completed two weeks of valganciclovir therapy with complete resolution of all symptoms.

Conclusions
===========

It has been hypothesized that appendicitis in HIV positive patients could be a result of IRIS, likely due to reactive lymphoid tissue in the appendix \[[@B20],[@B21]\]. Although CMV-IRIS in HIV-infected patients has been mostly reported as uveitis in those with CMV retinitis \[[@B22]\], appendicitis can be a rare manifestation of CMV in this clinical setting. This patient represents the first published case of appendicitis as a result of CMV-IRIS. Given the frequency of CMV co-infection and wide distribution of CMV in the gastrointestinal tracts of patients with AIDS, a proportion of excess cases of appendicitis in the HIV-infected population may be related to emergent immune responses to CMV after ART initiation.
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